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Abstract
Besides a fully processed, secreted form of clusterin (sCLU),
an alternative proapoptotic form of the protein targeting the
nucleus (nCLU) was recently described. The possible differen-
tial roles played by the two clusterin forms in growth and
motility of nonmalignant and malignant prostate cells are
investigated here. sCLU or nCLU was transiently transfected
in both androgen-independent prostate cancer cells (PC3 and
DU 145) and immortalized prostate epithelial cells (PNT1A,
a nontumoral control). Then, cell growth, motility, and cyto-
skeleton organization were studied. We found that (a) in
PNT1A cells, both sCLU and nCLU significantly decreased cell
proliferation and motility; (b) in PC3 and DU 145 cancer
cells, only nCLU inhibited cell growth and migration, with
sCLU being ineffective; and (c) the antimotility effect of nCLU
was accompanied by a dramatic dismantling of the actin
cytoskeleton. Moreover, transfection with ‘‘full-length’’ CLU
cDNA produced both sCLU and nCLU in nonmalignant PNT1A
cells, whereas only sCLU was found in cancer cells. Thus, CLU
gene expression might play a crucial role in prostate tumori-
genesis by exerting differential biological effects on normal
versus tumor cells through differential processing of CLU
isoforms in the two cell systems. We also found that nCLU
binds to A-actinin, a key protein for the regulation of actin
cytoskeleton, and that nCLU and A-actinin colocalize in the
cytoplasm. Thus, the antimotility activity of nCLU and its
ability to cause dismantling of the actin cytoskeleton seem
to be mediated by its binding to A-actinin. [Cancer Res 2007;
67(21):10325–33]
Introduction
Clusterin (CLU) is a gene/protein highly conserved and
expressed in several human tissues and fluids. Also known as
testosterone repressed prostate message 2, apolipoprotein J, or
sulfated glycoprotein 2 (1, 2), CLU has many biological functions
(1, 2). CLU is considered an enigmatic protein because of the
difficulties in the definition of its precise functions; at the moment,
an important debate concerns its implication in carcinogenesis,
particularly in prostate cancer development. On this issue, the data
currently available are controversial because CLU has been sug-
gested as being either a proapoptotic or a prosurvival factor (3–9).
The recent detection of two possibly related protein forms produced
by the same gene has depicted a new scenario that might help to
unravel its possible role. The CLU gene is located on human
chromosome 8 (10). CLU gene translation produces a protein
precursor that is driven by an initial signal peptide to the
endoplasmic reticulum, where it is cleaved into two distinct pep-
tides (a and h) held together by five disulfide bonds. The product
is then glycosylated, and the mature heterodimeric glycoprotein,
named sCLU, is secreted (1, 11, 12). An alternative isoform of
CLU has recently been identified and named nuclear CLU (nCLU;
refs. 13, 14). nCLU is synthesized from a second in-frame AUG codon
located in position 152. AUG152 becomes functional by (a) alter-
native splicing of CLU mRNA (13) or (b) alternative initiation of
translation (14). As a consequence, nCLU lacking the leader peptide
would not enter the endoplasmic reticulum, thus skipping a/h
cleavage and glycosylation, mainly localizing in the nucleus (1, 6, 9,
14, 15). The existence of sCLU and nCLU might explain the contra-
dictory roles apparently played by CLU gene in the control of cell
growth processes: sCLUwould act as a survival factor whereas nCLU
would be responsible for cell death induction (5–7, 9, 13, 15–18).
Prostate cancer is the second leading cause of male cancer
deaths in Western countries (19). The disease is initially androgen
dependent, and androgen-deprivation therapy represents the first-
line treatment for prostate cancer patients (20). After an initial
remission, prostate carcinoma progresses toward a condition of
hormone resistance, characterized by high proliferation rate, strong
metastatic behavior, and refractoriness to classic chemotherapy
(21). CLU level of expression has been found to be either down-
regulated (22–24) or up-regulated (25) in prostate cancer speci-
mens. Antisense oligonucleotides and small interfering RNAs
(siRNA) targeting the full-length CLU have been reported to induce
apoptosis and chemosensitivity in vitro in prostate cancer
xenografts (26–29) and in prostate cancer patients (30, 31). On
the other hand, nCLU accumulation has been observed in dying
prostate cells challenged with proapoptotic stimuli (4, 5, 17).
Overexpression of nCLU has been reported to induce G2-M phase
arrest and caspase-dependent apoptosis in prostate cancer cells
(6). Thus, although the role played by CLU gene in prostate cancer
development has not been fully clarified, the data currently
available suggest that the specific protein forms that are pre-
valently expressed within the cell and their subcellular localiza-
tion might be crucial for understanding the function(s) of this
enigmatic gene. As a confirmation of this, increase of nCLU expres-
sion during antisense oligonucleotide or siRNA targeting has been
considered as a possible explanation for chemosensitization of
breast cancer cells (32). These observations suggest that sCLU is
a prosurvival factor, whereas nCLU is proapoptotic. The relative
balance between sCLU and nCLU might drive cell fate and play an
important role in cell transformation.
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The aim of this work was to clarify whether, and through which
mechanisms, CLU gene plays a role in the control of growth and
metastatic behavior of prostate cancer cells. Thus, sCLU and nCLU
have been transiently overexpressed in prostate cancer cells (PC3
and DU 145) and in SV40-immortalized PNT1A prostate cells, a
nontumorigenic cell model. The biological effect of such maneuver
has been studied by evaluating cell growth, cell motility, and cyto-
skeleton organization. The results obtained have been interpreted
in relation to differential processing and intracellular localization
of clusterin in normal versus cancer cells.
In addition, we used the two-hybrid approach and coimmuno-
precipitation and colocalization analyses in the search for nCLU
binding partners and molecular interactions that might explain the
effects of this protein form on the migratory behavior of prostate
cells.
Materials and Methods
Materials
Antibodies used were mouse anti-human clusterin antibody (clone 41D,
Upstate Biotechnology); mouse anti-human actin antibody (clone Ab-1,
Oncogene); mouse anti-human a-actinin antibody (Chemicon Internation-
al); mouse anti-human pan-cytokeratin antibody (clone PCK-26, Sigma
Chemical Co.); polyclonal goat anti-human a-actinin antibody (C20, Santa
Cruz Biotechnology); and FITC-conjugated goat anti-mouse (Alexa Fluor
488), TRITC-conjugated goat anti-mouse (Alexa Fluor 594), and FITC-
conjugated rabbit anti-goat (Alexa Fluor 488) secondary antibodies
(Molecular Probes, Inc.). FITC-phalloidin, secondary horseradish peroxi-
dase–conjugated rabbit anti-mouse antibody, and laminin were from Sigma
Chemical. Fibronectin was from Biochrom.
Cell Cultures
PNT1A cell line was established by immortalization and cloning of
normal prostate epithelial cells with SV40 large T antigen (33, 34). PC3 and
DU 145 androgen-independent prostate cancer cells were purchased from
the American Tissue Culture Collection. PNT1A and PC3 cell lines were
routinely grown in RPMI 1640 supplemented with 10% fetal bovine serum
(FBS), glutamine (1 mmol/L), and antibiotics (100 IU/mL penicillin G
sodium and 100 Ag/mL streptomycin sulfate). DU 145 cells were grown in
the same medium supplemented with 5% FBS. Cells were incubated at 37jC
in 5% CO2.
Expression Vectors and Transfections
Full-length human clusterin cDNA was generated as described (15).
Briefly, reverse transcription-PCR of normal human fibroblast total RNA
was done using the primers 5¶-GACTCCAGAATTGGAGGCATG-3¶ ( forward)
and 5¶-ATCTCACTCCTCCCGGTGCT-3¶ (reverse). The cDNA was cloned
into pGEM-T Easy (Promega). CLU full-length cDNA was then subcloned
into the bicistronic expression vector pIRES-hyg (Clontech) to produce the
pIRES-sCLU vector. A truncated CLU cDNA fragment was then amplified
from the full-length expression vector using the primers 5¶-GTCTCAGA-
CAATGGGATCCAGGA-3¶ ( forward) and 5¶-GACCTGCAGGCGGCCGCGA-
AT-3¶ (reverse). Truncated cDNA was inserted in pIRES-hyg to generate the
pIRES-nCLU vector (6). Constructs have been sequenced before carrying out
expression experiments. Transfections were done with the nonliposomal
reagent FuGENE 6 (Roche). Cells (105) were plated in 35-mm dishes and
transiently transfected with 3 Ag/dish of plasmid DNA (pIRES-sCLU or
pIRES-nCLU). In each experiment, control cells were transfected with the
empty vector pIRES-hyg. Efficiency of transfection was routinely assessed by
green fluorescence protein (GFP) expression using the pCMV-GFP-LpA
vector (Clontech Laboratories). Transfection efficiency was usually higher
than 50% of total cells (6). The size of the pCMV-LpA vector is comparable
with that of the vector used for CLU overexpression. The high efficiency of
the procedure used is shown by the detection of the protein bands by
Western blotting (Fig. 1) and of CLU fluorescence signals by immunocyto-
chemistry (Figs. 3 and 4).
Cell Growth Assays
Transiently transfected PNT1A, PC3, and DU 145 cells, grown in 35-mm
dishes, were harvested and counted with a hemocytometer at different time
intervals (24–72 h) after transfection. Each experimental condition was
replicated six times and each experiment was repeated thrice. The data
were analyzed by one-way ANOVA followed by Bonferroni’s test.
Western Blotting
Whole-cell extracts. Transfected cells were lysed in radioimmunopre-
cipitation assay (RIPA) buffer [0.05 mol/L Tris-HCl (pH 7.7), 0.15 mol/L
NaCl, 0.8% SDS, 10 mmol/L EDTA, 100 Amol/L NaVO4, 50 mmol/L NaF,
0.3 mmol/L phenylmethylsulfonyl fluoride, 5 mmol/L iodoacetic acid] con-
taining leupeptin (50 Ag/mL), aprotinin (5Al/mL), and pepstatin (50 Ag/mL).
The extracts were centrifuged to remove insoluble material.
Culture media. Conditioned media obtained from transfected cell
cultures were centrifuged at 12,000  g for 10 min and 30 AL of super-
natants were processed for Western blotting. Pan-cytokeratin expression
was used as loading control.
Cytoplasm and nuclear extracts. Transfected cells were prepared using
the Nuclear Extraction kit (Chemicon International). Protein concentration
was determined using the bicinchoninic acid method.
Whole-cell extracts (30 Ag), culture media (30 AL), and cytoplasm and
nuclear extracts (50 Ag) were resuspended in sample buffer [0.5 mol/L
Tris-HCl (pH 6.8), 20% glycerol, 10% SDS, 0.2% 2h-mercaptoethanol, 0.05%
blue bromophenol] and heated at 95jC for 5 min. After electrophoretic
separation by 10% SDS-PAGE, proteins were transferred onto nitrocellulose
membranes. Membranes were blocked in 3% bovine serum albumin (BSA)
before incubation at room temperature for 2 h with the mouse anti-
clusterin primary antibody (1:1,000). Detection was done using a
horseradish peroxidase–conjugated anti-mouse secondary antibody and
enhanced chemiluminescence reagents (SuperSignal Chemiluminescence
Detection System, Pierce Biotechnology, Inc.). Lack of contamination by
cytoplasm proteins in nuclear extracts was monitored by Western blotting
of cytokeratin expression on membranes after stripping the blots and
blocking nonspecific sites. Mouse monoclonal anti-human pan-cytokeratin
was used at a dilution of 1:100,000.
Actin and a-actinin expression was detected in whole-cell extracts from
PC3 cells transfected with nCLU. Protein preparations (30 Ag) were pro-
cessed for Western blotting as described above with mouse anti-human
actin (1:5,000) or mouse anti-human a-actinin (1:1,000) as primary anti-
bodies, respectively.
Cell Migration Assays
Haptotactic assays were done using 48-well Boyden chambers (Neurop-
robe) inwhich each pair of wellswere separated by polyvinyl pyrrolidone–free
polycarbonate porous membrane (8 Am pore size). In preliminary experi-
ments, the most effective stimulus for PNT1A and PC3 cell lines was laminin
at 1.5 Ag/cm2; the best stimulus for DU 145 cells was fibronectin at 2.5 Ag/cm2
(data not shown). Thus, laminin was used for PNT1A and PC3 cells and
fibronectin was used for DU 145 cells. Transfected (48 h) cells were counted
and placed in the open-bottom wells of the upper compartment of a Boyden
chamber (105 cells/50 AL) in which the lower surface had been precoatedwith
either laminin or fibronectin. The lower compartment of the chambers was
filled with serum-free medium. The chambers were kept in the cell culture
incubator for 4 h. Cells that migrated through the pores and found adherent
to the underside of the membrane were fixed, stained (DiffQuick kit, DADE),
and mounted onto glass slides. Six random objective fields of stained cells
were counted for eachwell (eightwells per experimental group) and themean
number of migrating cells per square millimeter was calculated. Assays were
repeated thrice, and triplicate wells were analyzed for each time point. Data
were analyzed by one-way ANOVA followed by Bonferroni’s test. The effect of
clusterin isoform overexpression on cell migration is not explained by
decreased cell proliferation because the haptotactic assay is too short (4 h) for
detecting a possible antiproliferative effect.
Yeast Two-Hybrid Screen
For nuclear clusterin protein-protein interaction studies, we used the
MATCHMAKER GAL4 Two-Hybrid System 3 (Clontech). nCLU cDNA was
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cloned in NdeI and BamHI sites of pGBKT7 bait vector using the primers
5¶-ATGAGCTCCAGCATATGTCCAATC-3¶ ( forward) and 5¶-GCGGGATCCT-
CTAGTGCGG-3¶ (reverse). The resulting construct was used to screen a
human prostate cDNA library made in the pACT2 prey vector. Bait and prey
vectors were transformed in AH109 yeast strain and colonies were grown
and selected in media lacking adenine, histidine, leucine, and tryptophan.
Coimmunoprecipitation
Transfected (48 h) PC3 cells were lysed in RIPA buffer. Extracts were
centrifuged to pellet the cell debris. Protein extracts from supernatants were
incubated with anti-clusterin antibody (2 Ag) and rabbit anti-mouse
immunoglobulin G at room temperature for 2 h. Protein A-Sepharose beads
were added and incubated overnight at 4jC with gentle rotation. After
centrifugation, immunoprecipitated pellets were washed five times with ice-
cold wash RIPA buffer and thrice with water in a refrigerated microcentrifuge.
The pellets were dissolved in reducing sample buffer, electrophoresed, and
blotted onto nitrocellulose membranes. Membranes were blocked with 3%
BSA and incubated for 2 h at room temperature with mouse monoclonal
anti–a-actinin antibody (1:1,000). Membranes were then incubated with
rabbit anti-mouse secondary antibody for 1 h at room temperature. Signal
was detected with enhanced chemiluminescence reagents (SuperSignal
Chemiluminescence Detection System, Pierce Biotechnology).
Immunofluorescence Analysis
PNT1A, PC3, or DU 145 cells were seeded on 13-mm-diameter coverslips.
After transfection (48 h), cells were fixed with 3% paraformaldehyde in 2%
sucrose-PBS for 15 min and permeabilized with 0.5% HEPES/Triton buffer
(20 mmol/L HEPES, 300 mmol/L sucrose, 50 mmol/L NaCl, 3 mmol/L
MgCl2, 0.5% Triton X-100) for 1 min.
Detection of clusterin. Fixed cells were incubated with the unlabeled
monoclonal anti-clusterin primary antibody (1:100) followed by FITC-
conjugated goat anti-mouse secondary antibody (Alexa Fluor 488).
Detection of actin. Cells were seeded on coverslips coated with laminin
(1.5 Ag/cm2) and stained with FITC-phalloidin (1:2,000). In transfected PC3
cells, a-actinin was detected in fixed cells incubated with the unlabeled
monoclonal antibody (1:100) followed by TRITC-conjugated goat anti-
mouse secondary antibody (Alexa Fluor 594).
Analysis of nCLU/A-actinin colocalization. nCLU-transfected PC3
cells were fixed and incubated with the unlabeled monoclonal anti-clusterin
primary antibody (1:100) followed by TRITC-conjugated goat anti-mouse
secondary antibody (Alexa Fluor 594). Cells were then incubated with
the goat anti-human a-actinin primary antibody (1:100), followed by
FITC-conjugated rabbit anti-goat secondary antibody (Alexa Fluor 488).
In each experiment, labeled cells were examined under a Zeiss Axiovert
200 microscope with a 63/1.4 objective lens linked to a Coolsnap Es
charge-coupled device camera (Roper Scientific-Crisel Instruments).
Results
sCLU and nCLU overexpression in PNT1A and PC3 cells.
Cells were transiently transfected with either full-length CLU cDNA
(sCLU vector) or truncated clusterin cDNA (nCLU vector; ref. 6).
Protein expression was evaluated in whole-cell extracts from both
PNT1A and PC3 cells by Western blotting. The expression profile
of CLU in mock controls was identical to that in untransfected
cells for both cell lines (data not shown). Figure 1A shows that, in
both cell lines, transfection of the full-length cDNA (sCLU) leads,
48 h later, to overexpression of a protein band of f70 kDa,
corresponding to the predicted size of an intracellular sCLU pre-
cursor. As expected, the shorter ATG152 cDNA generated a smaller
protein form (nCLU), whose molecular weight was 49 kDa, which is
compatible with the predicted size of uncleaved, unglycosylated
nCLU (9). To further confirm correct processing and secretion of
sCLU, whole-cell extracts and conditioned culture medium
preparations from both cell lines at 48 and 72 h after transfection
Figure 1. A, Western blot analysis for determination
of sCLU and nCLU in nonmalignant (PNT1A) and
malignant (PC3) prostate epithelial cells. Whole-cell
extracts from transiently transfected (48 h) PNT1A
and PC3 cells were analyzed by SDS-PAGE and
Western blotting with a mouse anti-human clusterin
antibody. Western blot analysis of cytokeratin
expression is provided to show equal loading of the
samples. C, mock-transfected controls. Representative
of three different experiments done independently,
which gave the same results. B, Western blot analysis
for determination of sCLU in whole-cell extracts and
in culture media of nonmalignant (PNT1A) and
malignant (PC3) prostate epithelial cells. PNT1A and
PC3 cells were transiently transfected with sCLU
vector. Whole-cell extracts and culture media were
collected at 48 and 72 h after transfection. The
full-length cytoplasm sCLU isoform (70 kDa) and the
a chain of the secreted heterodimeric form (35 kDa)
were detected in cell extracts by SDS-PAGE and
Western blotting with a mouse antihuman clusterin
antibody. Representative of three different experiments.
Clusterin Isoforms and Prostate Tumorigenesis
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were analyzed by Western blotting. Figure 1B shows that sCLU is
overexpressed in cell extracts of both cell lines at 48 h after
transfection. In PNT1A cells, but not in PC3 cells, sCLU levels were
still elevated at 72 h. In culture media from both cell lines, a protein
band of f35 kDa, corresponding to the a chain of the mature
heterodimeric form of CLU, was particularly evident at 72 h after
transfection (Fig. 1B, Culture media). From Fig. 1B , it also seems
that sCLU is present in the culture media of control PNT1A cells,
but it is undetectable in the culture media of control PC3 cancer
cells. This observation might suggest that the ‘‘prosurvival’’ isoform
of clusterin is preferentially retained in the cytoplasm of cancer
cells, possibly to facilitate at this level their malignant potential.
As previously shown (6), the basal levels of the secreted form of
clusterin (corresponding to the endogenous secretion) were not
modified in the culture media of PNT1A and PC3 cells after
transfection with nCLU vector (data not shown), confirming that
nCLU was retained inside the cells instead of being secreted.
Effects of sCLU and nCLU on PNT1A, PC3, and DU 145 cell
growth. We checked whether the two clusterin isoforms might
differentially affect the growth of nonmalignant and malignant
cells. Figure 2A shows results obtained at 48 h after transfection
because, at this time interval, we observed the most significant
effects in all cell lines. Transfection of sCLU or nCLU vector caused
a significant decrease in PNT1A cell growth when compared with
mock controls (Fig. 2A). In PC3 and DU 145 cells, overexpression of
nCLU elicited a significant antiproliferative effect, whereas sCLU
did not affect cell proliferation (Fig. 2A). Thus, nCLU is antipro-
liferative in both nonmalignant and malignant prostate cells,
whereas sCLU is antimitogenic in normal, but not in malignant,
prostate cells.
Effects of sCLU and nCLU on PNT1A, PC3, and DU 145 cell
motility. PNT1A, PC3, and DU 145 cells transfected (48 h) with
sCLU or nCLU vector were subjected to haptotactic assay. The
results show that overexpression of both sCLU and nCLU sig-
nificantly decreases the migration of PNT1A cells when compared
with mock controls (Fig. 2B). In PC3 and DU 145 cells, cell motility
was significantly reduced only by nCLU, with sCLU being
ineffective (Fig. 2B).
Effects of sCLU and nCLU on actin cytoskeleton organiza-
tion in PNT1A, PC3, and DU 145 cells. Immunofluorescence
staining for F-actin was done in transfected (48 h) PNT1A, PC3,
and DU 145 cells. Figure 2C shows that mock-transfected PNT1A
cells (control) display a diffuse actin cytoskeleton with an intense
actin staining at the level of stress fibers and under the cell cortex.
sCLU and nCLU overexpression induced a dramatic change in
cell morphology and a decrease in intracellular actin staining,
indicating a complete disorganization of the actin cytoskeleton
(Fig. 2C). Figure 2C also shows the effects of sCLU or nCLU over-
expression on immunofluorescence staining of actin in PC3 and
DU 145 cells. In mock-transfected PC3 and DU 145 cells (control),
F-actin is widely diffused in the cytoplasm and localizes at the
cell periphery and at the level of filopodia. Transfection of PC3
and DU 145 cells with sCLU vector did not change actin organi-
zation; on the contrary, nCLU dramatically changed cell morphol-
ogy and completely disrupted the actin cytoskeletal organization
(Fig. 2C).
Intracellular localization of CLU isoforms in PNT1A, PC3,
and DU 145 cells. The differential effects of sCLU and nCLU on
growth and motility of normal and malignant prostate cells
suggested that full-length CLU cDNA might drive the synthesis of
both sCLU and nCLU in nonmalignant cells, whereas only sCLU
would be produced in cancer cells. To verify this hypothesis, the
intracellular localization of protein forms was analyzed in PNT1A
and PC3 cells by immunofluorescence and Western blotting after
transfection (48 h) with either sCLU or nCLU. In PNT1A cells,
transfection with sCLU originated a specific staining for CLU in the
cytoplasm (Fig. 3A, top, lane 1). However, a nuclear signal was
also observed in most of the cells (Fig. 3A, top, lanes 2 and 3).
Interestingly, when the protein staining was mainly present in the
cytoplasm, cells maintained their normal flattened shape (Fig. 3A,
top, lane 1). On the contrary, cells with clusterin also present in the
nucleus (Fig. 3A, top, lanes 2 and 3) showed an altered round shape
morphology, suggesting that these cells might undergo apoptosis
by anoikis as previously showed (3–5). Western blotting experi-
ments done on cytoplasm and nuclear extracts from PNT1A cells
overexpressing sCLU confirmed that these cells produced a protein
band of f70 kDa in the cytosolic fraction (Fig. 3A, bottom).
However, PNT1A cells also produced a protein band of f49 kDa,
corresponding to the molecular weight of nCLU. This band was
also present in the nuclear fractions (Fig. 3A, bottom). Thus, in
normal prostate cells, transfection with full-length cDNA originates
the cytoplasm ‘‘full-length’’ sCLU form and also a certain amount of
the shorter nuclear form of the protein. On the contrary, over-
expression of full-length cDNA in PC3 cancer cells only produced
a protein form off70 kDa, exclusively localized in the cytoplasm,
as shown by both immunofluorescence staining (Fig. 3B, top, lanes
1 and 2) and Western blotting of cytosol and nuclear extracts
(Fig. 3B, bottom). Thus, the nCLU isoform is produced by full-length
cDNA in the cytoplasm and then translocated into the nucleus only
in normal prostate cells. This does not happen in prostate cancer
cells. In contrast, transient transfection with nCLU cDNA was
followed by the immunofluorescence staining in the cytoplasm and
in the nucleus of both PNT1A and PC3 cells (Fig. 3C and D , top,
lanes 1 and 2). Western blot analysis further confirmed that a
protein band off49 kDa, corresponding to nCLU, is detectable in
the cytoplasm as well as in the nuclear fraction in both cell lines
(Fig. 3C and D, bottom). The same pictures show that, in mock
control cells, the endogenous 70-kDa band is detectable in PNT1A
cells and is known to express higher basal levels of CLU. In PC3
cells, the level of expression of endogenous CLU is much lower
instead. These data indicate that in both normal and cancer
prostate cells, nCLU cDNA gives rise only to the nuclear protein
isoform, which appears in the cytoplasm before being translocated
into the nucleus as previously suggested (9). In Western blotting
experiments, the lack of contamination of nuclear extracts by
cytosol proteins was verified by cytokeratin analysis.
The intracellular localization of CLU isoforms in DU 145 cells is
reported in Fig. 4. In DU 145 cells, sCLU was found to be exclusively
localized in the cytoplasm (Fig. 4, top, lanes 1 and 2), whereas nCLU
could be detected both in the cytoplasm and nucleus (Fig. 4,
bottom, lanes 1 and 2), in line with the results obtained in PC3 cells.
These results confirm that, in prostate cancer cells, the full-length
CLU isoform fails to give rise to the nuclear form of the protein
(as shown in normal prostate cells).
nCLU binds to and colocalizes with A-actinin. The possibility
that the nuclear isoform of clusterin might interact with a-actinin,
a protein involved in the organization of actin (35), has been
investigated in nCLU-transfected PC3 cells (in which only nCLU,
and not sCLU, was effective in disrupting actin cytoskeleton). We
investigated whether nCLU overexpression might affect the
expression of a-actinin by immunofluorescence analysis and
Western blotting. Figure 5A confirms that transfection of nCLU
Cancer Research
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dramatically changes cell morphology and disrupts the actin
cytoskeletal organization (F-actin). Figure 5A also shows that nCLU
does not affect a-actinin staining, which remains diffusely
distributed into the cytoplasm; nCLU-transfected cells (merge) do
not show a-actinin/actin colocalization. Both actin and a-actinin
protein levels were not affected by nCLU (Fig. 5B). These data
indicate that nCLU does not exert its effects on actin cytoskeleton
by reducing the expression of a-actinin.
We further analyzed whether nCLU might act by binding to
a-actinin; in fact, the ‘‘chaperone’’-like activity of clusterin has
already been shown in different experimental models (1). Results
from two-hybrid experiments indicated that a-actinin could be one
of the possible intracellular protein partners of nCLU (Fig. 6A).
Other potential protein partners of nCLU have also been detected
(Katanin p60, ZW10 interactor, and TRAF4-associated 1; further
experiments are ongoing to explore such molecular interactions).
To validate this observation, coimmunoprecipitation analysis was
done. Figure 6B (lane 2) shows that, in PC3 cells transfected with
nCLU, a-actinin specifically binds to nCLU. No coimmunoprecipi-
tation bands could be detected in negative controls (Fig. 6B, lane 1 ,
protein extracts from mock-transfected cells; lane 3 , no cell
extracts with anti-clusterin antibody; lane 4 , protein extracts
without anti-clusterin antibody). To further confirm these obser-
vations, colocalization analysis has been done by immunofluores-
cence. Figure 6C (lanes 1 and 2) shows that, after transfection,
nCLU is present in the cytoplasm before entering the nucleus
(nCLU); in both cells, nCLU substantially colocalizes with a-actinin,
mainly in the perinuclear region (Fig. 6C, lanes 1 and 2, merge).
Figure 6C (lane 3) shows a transfected PC3 cell in which most of
nCLU has already entered the nucleus. In this cell, no a-actinin/
nCLU colocalization can be detected at the cytosolic level (Fig. 6C,
lane 3, merge).
Figure 2. Effects of sCLU and nCLU
overexpression on proliferation (A), cell
motility (B ), and cell morphology and
actin cytoskeleton organization (C ) of
nonmalignant (PNT1A) and malignant
(PC3 and DU 145) prostate epithelial cells.
A, PNT1A, PC3, and DU 145 cells were
transiently transfected with sCLU or nCLU
vector and the cell number per well was
determined at 48 h after transfection. Each
experimental condition was replicated six
times and each experiment was repeated
thrice. Columns, mean number of cells per
well; bars, SE. C, mock-transfected cells.
B, PNT1A, PC3, and DU 145 cells were
transiently transfected (48 h) with sCLU
or nCLU vector and seeded in the upper
compartment of a Boyden chamber for
the haptotactic assay. Each experimental
condition was replicated six times and
each experiment was repeated thrice.
Columns, mean number of migrated
cells per square millimeter; bars, SE.
*, P < 0.05, versus mock-transfected cells.
C, immunofluorescence staining of F-actin
in mock-transfected (C ), sCLU-transfected
(sCLU ), and nCLU-transfected (nCLU )
PNT1A, PC3, and DU 145 cells 48 h after
transfection. In nonmalignant PNT1A cells,
both sCLU and nCLU induce a dramatic
change in the architecture and morphology
of the cells with a complete dismantling
of the actin cytoskeleton. In malignant
PC3 and DU 145 cells, at variance with
nonmalignant prostate epithelial cells,
sCLU does not change cell morphology
and F-actin organization. On the other
hand, as observed in nonmalignant
prostate epithelial cells, nCLU induces
a dramatic change in the morphology of
PC3 and DU 145 cells with a complete
disassembly of the actin cytoskeleton.
Representative pictures from three
experiments done independently, which
gave the same results.
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Discussion
We have studied how the two clusterin isoforms sCLU and nCLU
affect growth and motility of normal (PNT1A) and tumoral (PC3
and DU 145) human prostate epithelial cells. We found that nCLU
significantly decreased the growth of both normal and prostate-
cancer cells, confirming the peculiar antiproliferative/proapoptotic
functions previously hypothesized (7, 9, 13) and then described in
breast (12) and prostate cancer (6, 15) cells, also following different
proapoptotic stimuli (4, 5, 8, 17) or in other experimental models
(36–39). Transfection with sCLU vector differentially affected the
two cell models because accumulation of sCLU did not change
the proliferation rate of prostate cancer cells while eliciting a
Figure 3. A and B, intracellular localization of sCLU after transient transfection in nonmalignant (PNT1A; A) and malignant (PC3; B) prostate epithelial cells.
A, top, immunofluorescence detection of clusterin staining is reported for three different PNT1A cells (lanes 1–3) 48 h after transfection. Lane 1, clusterin
staining is mainly localized in the cytoplasm; the cell shows a normal flattened shape. Lanes 2 and 3, clusterin staining is detected not only in the cytoplasm but
also in the nucleus. These cells show a round shape morphology, typical of cells undergoing apoptosis and detaching from plate (lane 2) with condensed nucleus
(lane 3). Bottom, cytosol and nuclear extracts were prepared from PNT1A cells transfected (48 h) with sCLU and submitted to Western blot analysis. As expected,
a protein band of 70 kDa accumulated in the cytosolic fraction of transfected PNT1A (sCLU) when compared with mock-transfected controls (C). Interestingly,
a band of f49 kDa, corresponding to the molecular weight of the nuclear form of the protein, is also present in both the cytosol and the nuclear fraction of the
cells. Representative pictures from three experiments done independently, which gave the same results. B, top, immunofluorescence detection of clusterin staining
is reported for two different PC3 cells (lanes 1 and 2) 48 h after transfection. In both cells, clusterin staining is exclusively localized in the cytoplasm. Bottom, cytosol
and nuclear extracts were prepared from PC3 cells transfected (48 h) with sCLU and submitted to Western blot analysis. As expected, transfection leads to accumulation
of a protein band of 70 kDa exclusively in the cytosolic fraction of transfected PC3 cells as compared with mock-transfected controls. This band is absent in nuclear
extracts from the same cells. No band of 49 kDa can be detected in the cytosolic or nuclear fraction of PC3 cells. Representative pictures from three experiments
done independently, which gave the same results. C and D, intracellular localization of nCLU after transient transfection in nonmalignant (PNT1A; C) and malignant
(PC3; D) prostate epithelial cells. C, top, immunofluorescence detection of clusterin staining is reported for two different PNT1A cells (1, 2) 48 h after transfection. In both
cells, clusterin localizes both in the cytoplasm and in the nucleus. Bottom, cytosol and nuclear extracts were prepared from PNT1A cells transfected (48 h) with nCLU
and submitted to Western blot analysis. A protein band of 49 kDa clearly accumulates in both the cytosolic and nuclear fractions of transfected PNT1A cells (nCLU).
This band is completely absent in mock-transfected controls. Representative pictures from three experiments done independently, which gave the same results. D, top,
immunofluorescence clusterin staining is reported for two different PC3 cells (lanes 1 and 2) at 48 h after transfection. As previously observed in nonmalignant cells,
the two PC3 cells show positive clusterin staining, detectable both in the cytoplasm and nucleus. Bottom, cytosol and nuclear extracts were prepared from PC3 cells
transfected (48 h) with nCLU and submitted to Western blot analysis. Following transfection, a protein band of 49 kDa clearly accumulates both in the cytosol and nuclear
fractions of PC3 cells when compared with mock-transfected controls. Representative pictures from three experiments done independently, which gave the same
results. Western blot analysis of cytokeratin expression is provided to show absence of cross-contamination of nuclear extracts.
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significant decrease in cell growth in nonmalignant prostate cells,
as previously reported (3). The lack of effect of sCLU on the growth
of cancer cells is consistent with previous observations indicating a
prosurvival, antiapoptotic effect of this protein form. Transfection
of sCLU in cancer cells is associated with increased survival in the
presence of cytotoxic drugs (40–42), whereas down-regulation of
sCLU by means of antisense oligonucleotides decreases drug
resistance in cancer models (27, 28, 32, 42–47).
Then, we investigated whether or not the two protein isoforms
modulate cell motility and cytoskeletal organization. We found that
nCLU caused a significant decrease in cell motility in both non-
malignant and malignant prostate cells. This effect was accompa-
nied by a dramatic alteration of cell morphology and complete
dismantling of actin cytoskeleton. In contrast, the sCLU form
exerted an antimigratory effect only in normal, and not in tumor,
prostate cells. It is important to take into account that the modality
of induction of cell death by nCLU has previously been
characterized. In previous works (9, 10, 14), it has been shown
that nCLU induces anoikis, a cell detachment–induced cell death
that takes from 24 h to a few days to be fully appreciated in
prostate cells. Only when Ca2+ is fully depleted by BAPTA-AM is
the phenomenon much faster (17). This important information is
given here to exclude the possibility that the antimigratory effect
detected in our experiments (which lasted 4 h) is biased by a
specific loss of CLU-overexpressing cells. The experimental data
thus far available on the possible role played by the secreted form
of the protein in the control of cell motility are scarce and rather
controversial. Overexpression of sCLU has been reported either to
inhibit (48) or to stimulate (16, 49) the metastatic behavior of can-
cer cells. The reasons for this discrepancy are not clear; however,
the different experimental conditions used need to be carefully
considered in the final interpretation of the data.
The relative lack of production of the nuclear form of clusterin
in prostate cancer cells suggests that full-length clusterin cDNA
and/or protein precursor might be differentially processed in
normal versus transformed cells. We observed that transfection
of full-length CLU cDNA only resulted in production of a protein
band off70 kDa (corresponding to the full-length isoform) in pro-
state cancer cells, which was exclusively localized in the cytoplasm
and then converted into the fully processed and secreted clusterin
(sCLU) form of the protein. On the contrary, normal PNT1A cells
produced not only the expected cytoplasm precursor and the
secreted form but also a protein product of 49 kDa corresponding to
the nuclear form of clusterin. This 49-kDa protein band was found
both in the cytoplasm and in the nuclear extracts, confirming that
nCLU is synthesized as a precursor cytoplasmic protein, which is
then translocated (on activation?) into the nucleus (9). A similar
intracellular distribution of clusterin (i.e., cytoplasmic and nuclear
localization) was observed after transfection of the nCLU cDNA
both in normal and cancer cells. Because we have shown that nCLU
reduced cell motility by acting on the cytoskeleton organization, we
hypothesize that this protein isoformmight exert these effects when
still present in the cytoplasm.
In normal prostate cells, the full-length CLU gene originates
both the secreted (and probably cytoprotective) and the truncated
antimitogenic/antimigratory form of the protein, which is known
to localize into the nucleus to exert its potent effects. Thus, a shift
in the production of CLU isoforms may play a crucial role in
Figure 5. Effects of nCLU overexpression on a-actinin expression in malignant
PC3 prostate epithelial cells. A, immunofluorescence staining of F-actin and
a-actinin in mock-transfected (C ) and nCLU-transfected (nCLU ) PC3 cells
48 h after transfection. The dramatic effect of nCLU on cell morphology and
actin cytoskeleton organization is not accompanied by alteration of a-actinin
staining; however, nCLU-transfected cells (Merge ) do not show a-actinin/actin
colocalization. B, Western blot analysis of actin and a-actinin expression in PC3
cells transfected with nCLU. The expression of both proteins is not affected by
nCLU overexpression. Representative pictures from three experiments done
independently, which gave the same results.
Figure 4. Intracellular localization of sCLU and nCLU after transient transfection
(48 h) in DU 145 prostate cancer cells. Top, immunofluorescence detection of
clusterin staining is reported for two different DU 145 cells (lanes 1 and 2)
transiently transfected with sCLU. In both cells, clusterin staining is exclusively
localized in the cytoplasm. Bottom, immunofluorescence detection of clusterin
staining is reported for two different DU 145 cells (lanes 1 and 2) transiently
transfected with nCLU. The two DU 145 cells show positive clusterin staining,
detectable both in the cytoplasm and in the nucleus.
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keeping a balance between cell proliferation and cell death, deeply
affecting the cell fate. In this view, neoplastic transformation of
prostate cells might require early escape from this mechanism,
with the prosurvival sCLU action prevailing over the proapop-
totic/antimotility properties of nCLU. Under these conditions,
nCLU might not be efficiently produced and/or translocated into
the nucleus. In line with our observations, it has been reported
that healthy colonic mucosal cells display a strong nuclear locali-
zation of clusterin, consistent with its role in apoptosis induction;
progression toward high-grade colon carcinomas is characterized
by appearance of the cytoplasm form of clusterin, accompanied
by a complete loss of the nuclear isoform (50). The molecular
mechanisms responsible for the shift in clusterin isoform syn-
thesis are still unclear. Leskov et al. (13) have suggested that
nCLU might originate from the full-length CLU gene by alternative
splicing of CLU mRNA. The experimental conditions adopted in
the present article (transfection with the full-length CLU cDNA)
strongly support an alternative initiation of translation. This point
is crucial for cell transformation and deserves further studies.
Because nCLU was found to be associated with decreased
motility and a dramatic disassembly of the actin cytoskeleton, we
investigated the possible mechanism of this activity. We found that
nCLU specifically binds to and colocalizes with a-actinin, an actin-
cross-linking protein, which plays crucial roles in regulating
plasticity of the actin cytoskeleton (35). We hypothesize that
binding of nCLU to a-actinin would reduce its ability to cross-link
actin filaments, thus promoting cytoskeletal disassembly and
decreased motility. Because the binding of nCLU to a-actinin is
specifically localized in the cytoplasm, we suggest that nCLU might
exert its effects on the cytoskeletal organization when still in the
cytoplasm and before entering the nucleus. These results show for
the first time that nCLU is an a-actinin binding protein causing
disassembly of the cytoskeleton. The finding that nCLU reduces
the motility of the cells provides a rationale for anoikis-death induc-
tion previously described when nCLU was induced (4, 5, 8, 17, 37).
Because of the controversy about the possible proapoptotic
versus antiapoptotic role for this protein, and the down-regulation
versus up-regulation of CLU gene in prostate cancer, unraveling the
role of CLU in prostate tumorigenesis is critical. In this light, it is
important to consider that clinical trials aimed at inhibiting CLU
expression with antisense oligonucleotides are ongoing in prostate
cancer patients (30). Chi and coworkers showed that it is possible
to achieve a significant down-regulation of CLU and increased apo-
ptotic rate in prostate cancer cells without major adverse effects for
patients. Unfortunately, the relative percentages of sCLU and nCLU
affected by this down-regulation are not known. Our results suggest
that prostate cancer patients would benefit from an ideal scenario
where sCLU is knocked down while nCLU is up-regulated. Lowering
the sCLU/nCLU ratio might be the right strategy to control prostate
cancer cell outgrowth and metastatic diffusion.
In conclusion, the data reported here represent the first
demonstration that the proapoptotic nuclear isoform of clusterin
is endowed with a potent antimigratory activity through binding
to a-actinin. Moreover, the pattern of clusterin isoform production
Figure 6. Binding of overexpressed nCLU
to a-actinin in malignant PC3 prostate
epithelial cells. A, yeast two-hybrid analysis
of nCLU interactions with a-actinin. AH
109 yeast strain was selected for growth
on SD/Leu, Trp, His, Ade with
10 mmol/L 3-amino-1,2,4-triazole. Positive
control was done by cotransfection of
pBD-SV40 as bait vector with pAD-p53
as prey. The negative control consisted
of nCLU (bait) with empty pACT2 vector
(prey). B, coimmunoprecipitation
experiments on PC3 cells transiently
transfected (48 h) with nCLU. Protein
extracts from transfected PC3 cells were
immunoprecipitated with anti-clusterin
antibody, resolved by SDS-PAGE, and
processed for immunoblotting with
anti–a-actinin antibody (lane 2). No
coimmunoprecipitation bands can be
detected in negative controls: lane 1,
protein extracts from mock-transfected
PC3 cells; lane 3, no cell extracts with
anti-clusterin antibody; lane 4, protein
extracts from nCLU-transfected cells
without anti-clusterin antibody.
Representative pictures from three
experiments done independently,
which gave the same results. C,
immunofluorescence staining of nCLU and
a-actinin in nCLU-transfected malignant
PC3 prostate epithelial cells. Lanes 1
and 2, in these cells, nCLU is still localized
in the cytoplasm before entering the
nucleus (nCLU); nCLU and a-actinin
substantially colocalize at the cytoplasmic
level (Merge), mainly in the perinuclear
region. Lane 3, in this cell, nCLU is already
localized in the nucleus; no colocalization
with a-actinin (Merge) at the cytoplasmic
level. Representative pictures from three
experiments done independently, which
gave the same results.
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is different in normal versus cancer prostate cells; escaping the
mechanisms leading to nCLU production from the full-length CLU
gene might play a crucial role in prostate tumorigenesis.
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